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sulphonylureas were less likely to be persistent than those initiated on metformin 
(OR= 0.50; 95%CI= 0.45 to 0.54; p< .0001). ConClusions: Persistence amongst newly 
treated T2DM patients appears to be low. Type of OHM, age and scheme were all 
significantly associated with persistence. Prescribers should pay particular atten-
tion to newly treated patients covered under the GMS scheme, at the extremes of 
age and those initiated on sulphonylureas.
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objeCtives: The impact of memory problems (MPs) on patient’s insulin taking 
behavior, functioning, well-being and diabetes management is not well under-
stood. Methods: A 5 country web-based survey was conducted. MPs were defined 
as: unintentionally forgetting (UF) to take insulin, questioning whether or not 
insulin had been taken (QT), or questioning how much insulin dose was taken 
(QD). Data from Canadian respondents were analyzed and compared to the other 
countries (US, UK, Germany, and China). Results: A total of 350 respondents in 
Canada completed the survey (74.0% Type 1, 52.0% male, mean age of 37.1 years, 
mean age of diabetes onset of 24.2). The prevalence of MPs was 60.6% (UF), 76.3% 
(QT) and 44.6% (QD) in the past month with only approximately 1/3 being confi-
dent they knew what to do when having an MP. Between 21.5% (QT) and 37.4%(UF) 
tested their blood glucose and 32.6% (QD) – 51.6% (QT) skipped their insulin dose 
and waited for next scheduled dose when experiencing a MP, requiring, on aver-
age, between 8.5 (QT)–19.1 (UF) hours for return to normal blood glucose ranges. 
Patients conducted between 1.9 (QT) –5.0 (UF) extra BG monitoring tests the week 
following the MP and reported moderate negative impacts on their ability to 
work, physical and emotional functioning. Up to 13.7% missed a work day (UF) 
and between 10.8% (QT) and 16.8% (UF) visited their health care provider as a 
result of MP Compared to respondents in the other countries (N= 1404), Canadian 
respondents were reported significantly longer recovery times for returning to 
normal blood glucose levels following a MP and were significantly more likely 
to experience hyperglycemia following UF/QD than patients in other countries 
(p< .05). ConClusions: These findings suggest that MPs have economic implica-
tions, impact patients’ functioning and well-being and may be serious obstacles 
to optimal diabetes control.
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objeCtives: The impact of memory problems (MPs) on patient functioning, well-
being and diabetes management is not well understood. The purpose of this study 
was to examine these impacts in the UK and compare these findings to data 
from US, Germany, Canada, and China). Methods: A 5 country web-based survey 
examining MPs was conducted. MPs were defined as: unintentionally forgetting 
(UF) to take insulin, questioning whether or not insulin had been taken (QT), or 
questioning amount of insulin dose (QD). Results: A total of 350 UK respondents 
(52.0% Type 1), 49.1% male, mean age of 40.3, mean age of diabetes onset of 25.5 
completed the survey. The prevalence of MPs was 66.6% (UF) forgetting, 84.9% (QT) 
56.9% (QD). MPs occurred most frequently when relaxing or doing household jobs. 
Between 13.7% (UF) – 32.6% (QT) of respondents skipped their insulin dose due 
to a MP and required between 1.4 (QD)–13.1 (UF) hours, on average, to return to 
normal blood glucose range. As a result of a MP, patients conducted between 1.7 
(QT) –6.8 (UF) extra BG monitoring tests , reported a moderate negative impact on 
their physical and emotional functioning, as well as their ability to go to or func-
tion optimally at work and between 8.1% (QT) and 20.0% (UF) visited/contacted 
their health care provider . Economic implications include cost of additional BG 
strips, lost work productivity and health care resource utilization. Compared to 
respondents in the US, Germany, China and Canada (N= 1404), UK respondents 
conducted significantly more BG tests during the week following a missed dose 
of insulin were more likely to take a dose of insulin following a MP without test-
ing their BG. ConClusions: These findings suggest that MPs in the UK carry 
financial burden, impact patients’ daily functioning and well-being and may be 
serious obstacles to optimal diabetes control.
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objeCtives: To compare antidiabetic treatment compliance with regards to the 
fixed or free treatments combination. Methods: A retrospective study based on 
the IMS LifeLinkTM Diabetes Cohort linked to IMS Disease Analyzer, a longitudinal 
patient database containing the electronic health records of patients followed-up 
by a representative panel of French general practitioners. Two cohorts of patients 
treated both with metformin and DPPIV were constituted, the first one treated with 
fixed associations (“fixed cohort”), the second one treated with free associations 
(“free cohort”). Study investigated patients’ demographic and clinical character-
istics, conditions of use, persistence rates, medication possession ratio (MPR) and 
proportion of days covered (PDC) of the two cohorts. Results: Respectively 2 234 
and 8220 patients have been treated with free and fixed antidiabetic associations 
between 2007 and 2013. Patients are significantly older (66 vs. 64 years, p< 0.01) in 
the free cohort where the proportion of men is significantly lower (56% vs. 63%, 
p< 0.0001). Nevertheless diabetes oldness is the same (about 10 years) in both 
system structure and in cost transparency, the cost estimation methodology varied 
among countries. One limitation of this study is that diagnostic related group (DRG) 
tariffs were used to estimate several costs, which may not accurately represent the 
burden of a specific complication nor take into account the full burden of follow-up 
after an acute event.
PDB72
The cosT of sPecIalIzeD hosPITal care for PaTIenTs wITh DIaBeTIc 
fooT Ulcers In rUssIa
Ignatyeva V.1, Avxentyeva M.1, Omelyanovsky V.V.1, Galstyan G.R.2
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia, 2The Endocrinological Scientific Center, Moscow, Russia
objeCtives: To assess the direct medical costs for aggressive limb preservation 
treatment of diabetic foot ulcer (DFU) in a highly-specialized hospital setting in 
Russia Methods: A retrospective data analysis of 156 admissions during 1-year 
period was done to get direct costs (associated with hospital stay, conservative 
and surgical treatment and laboratory testing) for treatment of DFU in a highly-
specialized inpatient department in Russian setting (Federal Endocrinology 
Centre). Results: The median cost of hospital treatment was 2270 EUR and 
increased with severity level, defined according to Wagner classification, ranging 
from 1590 EUR (grades 0-2) to 3812 EUR (grade 3) and 7683 EUR (grade 4), the differ-
ence was statistically significant. The length of stay in a hospital also correlated 
with the severity level starting with 14 days for grade 1 and reaching 39 days for 
grade 4. The costs of treatment were significantly higher for patients with inad-
equate vascular status requiring surgery – the median was 6185 EUR for cases with 
only angioplastic surgery and 8622 EUR for cases with both angioplastic and foot 
surgery provided. ConClusions: Treatment of DFU aimed at limb preservation is 
resource consuming, costs for treating severe stage ulcer are 4,8 times higher than 
are those for treating low-stage ulcer. The high costs of treating severe stages of 
DFU in a specialized hospital setting emphasize the value of intensive outpatient 
interventions designed to prevent ulcer progression.
DIaBeTes/enDocrIne DIsorDers – Patient-reported outcomes &  
Patient Preference studies
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objeCtives: Previous studies have shown that only a small number of pediatric and 
young adult patients discontinue pump therapy, but risk factors for discontinuation 
are unclear. Aim of this study was to identify characteristics of pediatric and young 
adult patients with pump therapy which are associated with discontinuation of 
treatment. Methods: Retrospective cohort study using a representative nation-
wide database (LRx; IMS Health) in Germany covering > 80% of all prescriptions to 
members of statutory health insurances in 2008-2011. All patients (age groups: < 6, 
6-< 12, 12-< 18, 18-< 25 years) with new prescriptions of insulin pumps or related 
material were identified (2009-2011) and were followed for ≥ 12 months. Results: 
Overall, 3057 new pump users were identified, of whom 177 (5.8%) switched to other 
forms of insulin therapy within 12 months. Discontinuation was lowest in the age 
group < 6 years (2.1%) and was highest in adolescents (12-< 18 years: 7.5%) (p< 0.01). 
In age-adjusted logistic regression, usage of steel needles (Odds ratio, OR, 95%CI: 
1.69; 1.20-2.44) and prescriptions of antiepileptics (3.14; 1.49-6.59) were related to 
pump discontinuation. In younger age groups only, discontinuation was signifi-
cantly higher in patients with thyroid therapy as a surrogate measure for thyroid 
autoimmunity (< 6 years: 14.3%; 6-< 12 years: 25.0%) (p< 0.01). ConClusions: About 
94% of pediatric and young adult patients maintained insulin pump therapy within 
12 months. Adolescence (12-18 years), usage of steel needles and prescriptions of 
antiepiletic drugs are independent predictors of discontinuation. In younger age 
groups (< 12 years) also thyroid therapy (indicating autoimmunity) was related to a 
higher risk of discontinuation.
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objeCtives: To describe persistence patterns to OHM in newly treated Irish patients 
with T2DM. The study also investigated the effect of age, gender, reimbursement 
scheme and type of OHM on persistence. Methods: A population based retrospec-
tive cohort study was conducted using national pharmacy claims databases, includ-
ing two community drugs schemes; Long Term Illness, (LTI, non-means tested) and 
General Medical Services (GMS, means tested). Newly treated T2DM patients were 
identified for 2008-2009, having received no OHM in the previous year, and followed 
up until Nov-2012. Patients who subsequently switched or received additional OHM 
were excluded. Non-persistence was defined as a prescription gap of > 12 weeks 
and within 1 year of initiating treatment. Logistic regression examined associations 
of age, gender, scheme and type of OHM with persistence with results presented 
as odds ratios (OR) and 95% confidence intervals (CI). Results: A total of 15,174 
persons were eligible for the study. Most patients were initiated on metformin 
(79.4%) and sulphonylureas (19.1%). Persistence at 1 year was 60.9%. The median 
overall time to non-persistence was 51.5 days. Men were slightly more likely to 
be persistent than women (OR= 1.08; 95%CI= 1.001 to1.15; p= 0.0025). Patients aged 
16-44 and 75+ were less likely to be persistent than patients aged 55-64 (OR= 0.18; 
95%CI= 0.16-0.21; p< 0.0001 and OR= 0.67; 95%CI= 0.60-0.75; p< 0.0001 respectively). 
Patients registered with the LTI Scheme were more likely to be persistent than 
from the GMS Scheme (OR= 1.35; 95%CI= 1.20-1.51; p< 0.0001). Patients initiated on 
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daytime and nocturnal hypoglycaemia. Non-linear regression curves were fitted 
to the total disutility of different frequencies of hypoglycaemic events. A weight-
ing scheme was used to allow each data point (one event quarterly, one monthly, 
one weekly or three weekly) to reflect the range of hypoglycaemic frequencies the 
data point represented. Non-parametric bootstrapping was applied to character-
ise the uncertainty of the marginal disutility. Results: Power function regres-
sion curves were estimated at Ud= 0.0141x0.3393 and Ud= 0.0221x0.3277, where Ud is 
disutility and x is the annual hypoglycaemic event rate, for non-severe day-
time and non-severe nocturnal events. An increase from 0 to 1 hypoglycaemic 
events per year, produced a utility decrease of 0.0141 for non-severe daytime, 
and 0.0221 for non-severe nocturnal, whereas an increase of one hypoglycaemic 
event per year for a patient who experiences 25 hypoglycaemic events per year 
produces a marginal impact of 0.0006 and 0.0008 for non-severe daytime and 
non-severe nocturnal, respectively. ConClusions: If patient-level data are avail-
able, non-linear functions estimated with TTO data might improve the precision 
of the measured impact of hypoglycaemic events. The results seen here illustrate 
diminishing marginal disutility with increasing numbers of hypoglycaemic events. 
This fits with the phenomenon of “first being worst” with regards to hypogly-
caemia.
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objeCtives: To compare the health related quality of life (HRQoL) in Polish patients 
with type 2 diabetes (T2D) and in matched sample from the general popula-
tion. Methods: Data on HRQoL came from two non-interventional studies: pro-
spective study of patients with T2D and EQ-5D Polish general population norms 
study. Analysis of HRQoL was conducted in four separate age groups: 32–44, 45–54, 
55–64 and above 65 years. We analyzed: an subjective and objective assessment 
of HRQoL (EQ VAS and EQ-5D index) and the presence of restrictions within five 
dimensions of the EQ-5D descriptive part. Results: A total of 274 patients with T2D 
and 214 representatives from population norms study, were included. EQ VAS was 
systematically lower in diabetic patients compared to the general population, and 
decreased with age (68.2 vs 83.9, 62.4 vs 79.2; 54.9 vs 78.1, 50.2 vs. 69.8 in consecutive 
age groups). A similar relationship was observed with EQ-5D index. The largest mean 
differences were observed among subjects aged 55-64 years (EQ VAS: 23.2, EQ-5D 
index: 0.085). In three domains: self-care, usual activities and anxiety/depression, 
patients with diabetes above 45 years of age, reported significantly more problems 
than respondents from the general population. ConClusions: Both subjective 
and objective HRQoL in patients with T2D is lower than in respondents of similar 
age from the general population. Compared with type 2 diabetic populations from 
other countries, Polish patients characterize by a relatively high HRQoL objective 
assessment and very low subjective assessment.
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objeCtives: The impact of Type 2 diabetes mellitus (T2DM) on health related quality 
of life (HRQL) is complex due to the burden of disease, lifelong treatment require-
ments and comorbidities. This study aimed to capture UK societal utility values for 
health states associated with T2DM and treatment-related adverse events (AEs) to 
assess the burden of the disease and common AEs. Methods: Nine health state 
descriptions were developed (from a literature review and patient and clinician 
qualitative input) depicting the burden associated with T2DM and treatment related 
AEs. These were mild/moderate urinary tract infection (UTI); severe UTI; mycotic 
infection; moderate hypoglycaemic events; severe hypoglycaemic events; fear of 
hypoglycaemia; gastrointestinal symptoms; and hypovolaemic events. Members 
of the UK general public (n= 100) valued these states using the time trade-off (TTO) 
methodology to elicit utility values (between 0= dead, 1= full health). Regression 
analysis was conducted to understand influence of age and gender. Results: All 
treatment-related AEs were found to have a significant effect on utility. From the 
T2DM baseline state (0.92), the experience of AEs was associated with the follow-
ing disutility: T2DM with hypovolaemic events (0.08); T2DM with mild/ moderate 
UTIs (0.09); T2DM with moderate hypoglycaemic events (0.11); T2DM with severe 
hypoglycaemic events (0.15); T2DM with fear of hypoglycaemia (0.15); T2DM with 
severe UTIs (0.19); T2DM with GI symptoms (0.24); andT2DM with mycotic infection 
(0.25); Males consistently scored the states with significantly lower utility values, but 
no significant age effects emerged. ConClusions: Findings suggest that adverse 
events in T2DM can be a burden for some individuals. The study indicates the poten-
tial importance of including information regarding AEs in economic evaluations. 
Although some states were rated severely in terms of utility, in reality, many of 
these only last a few days, therefore having a minimal quality adjusted life year 
(QALY) impact.
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cohorts. Daily number of prescribed tablets whatever the therapeutic classes is 
significantly higher in the free cohort (4.4 per day vs. 3.1, p< 0.01). At the end of the 
first treatment year, significantly more patients of the fixed cohort are still treated 
by the same association regardless daily dosages or potential add-on treatments 
(85% vs. 72%, p< 0.0001); moreover MPR is the same in both free and fixed cohort 
(64% and 66% without statistical difference) while PDC is significantly higher in 
the fixed cohort (60% vs. 54%, P< 0.0001). ConClusions: Patients treated by fixed 
antidiabetic treatments associations seem to be more persistent than these 
treated by free ones at the end of the first year of treatment. These results will be 
consolidated soon by comparing two similar sub-cohorts with the same medical 
profile.
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objeCtives: Low adherence to medications in chronic diseases is a well docu-
mented problem that diminishes drug actions. Understanding the factors that 
can impact adherence is a priority in order to improve it. Diabetes adherence can 
be influenced by the complexity of administration of some medications as well 
as patients’ attitudes and doctor/patients interaction. This study evaluates the 
influence of the following variables in the adherence of people with diabetes: 
Dosage, patient age, gender, substance, price of drug, pack size, pack strength 
and doctor specialty. Methods: Adherence was calculated using the medical 
possession ratio (MPR) = unique days of therapy/available days. A logistic regres-
sion was conducted to explore the multiple variables affecting the MPR. Results: 
The analyses included 25 months (from July 2009 to July 2011) of longitudinal 
prescription data for Germany for the ATC class A10 (oral antidiabetic). We found 
significant effects on adherence for age groups 55-64 (0.0909 p< 0.01), 65-74 (0.1266, 
p< 0.0004) and > 75 (0.0868, p< 0.0155), dosage (-0.7646, p< 0.0001), gender (-0.0493 
p< 0.001), pack size (0.0119, p < 0.0001), doctor specialty (0.0251, p< 0.0286) and 78% 
of all substances. ConClusions: Adherence seems to be negatively influence 
by dosage and younger age groups. Price does not seem to have an influence. 
Perhaps this is because the health care system in Germany reimbursed all oral 
antidiabetics. Metformin has the greater odds for poor adherence aside from the 
substances “glitazones”. Lower adherence rate might be negatively influenced 
by the recent warnings for Glitazones. Gender is a weak predictor for adherence. 
When comparing specialists with general practitioners, the odds of adherence are 
not very different between them (slightly positive towards the specialist group_ 
coeff 0.0251, p< 0.0286). This could be related to the diabetes management plan 
that exists in Germany since 2003, which has several aspects, from support to 
clinicians to training of patients.
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objeCtives: Diabetes is a chronic illness and 15% of diabetic will develop foot 
ulceration at some point of their life. Poor psychosocial states have been identi-
fied as one of the major risk factors for foot ulcers. Good, regular foot care, strict 
metabolic control and better adjustment to illness can prevent or reduce suffering 
effect of the illness. The purpose of this study was to compare the psychosocial 
adjustment to illness between diabetic patients with and without diabetic foot ulcer 
(DFU). Methods: A case-control study was conducted in a tertiary care teaching 
hospital in South India for a period of one year. Psychosocial Adjustment to Illness 
Scale-Self Report ( PAIS-SR) were used to assess psychosocial adjustment to illness. 
DFU patients (Case) who admitted in the surgery units were included. Diabetic 
patients without foot ulcers (control) were selected from medicine units during the 
same period. Results: The study participants were 84 people with diabetic foot 
ulceration and 84 people without diabetic foot ulceration. There were no significant 
differences between the two groups for gender, age and marital status. A significant 
difference was found between two groups for education level (p= 0.001) occupational 
status (p= 0.045). A significant difference was found between the groups in relation 
to smoking (p= 0.000) and drinking (p= 0.000). There were a significant difference 
seen in PAISSR scores ( lower scores means better adjustments) between the two 
groups (p= 0.000) representing subjects without DFU had better psychosocial adjust-
ment than subjects with DFU. ConClusions: The study concluded that compared 
to patients without DFU, patients with diabetic foot ulcer had poorer metabolic 
control, low educational level, bad social habits. Longer duration of diabetes, longer 
period of hospitalization, low level of disease knowledge and more incidence of 
comorbid conditions.
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objeCtives: Hypoglycaemic events are proven to have a negative impact on 
the health-related quality of life (HRQoL) of patients with diabetes. The negative 
impact of hypoglycaemia on HRQoL may be evaluated via disutility scores. The 
aim of this study was to assess the marginal impact of non-severe hypoglycaemic 
events on HRQoL and to investigate the functional form of the disutility of hypo-
glycaemic events. Methods: Published disutility values from a large-scale, web-
based time-trade-off study (TTO) conducted in UK, USA, Canada, Germany and 
Sweden with 8,286 respondents, were used as a basis for the analysis of non-severe 
